Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder

Overview of attention for article published in BMC Psychiatry, November 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 56 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 32,099 followers.

スゲェ

14 Nov 2020

Reply Repost Favourite

RT @Fizz_DI: 「チペピジン」の咳止めとしての効果を調べようと思って論文を漁っていると、徐放剤がADHD治療薬として研究されていることを知って驚いている(´･ω･`) < drug repositioning BMC Psychiatry . 2020 Nov 10…

14 Nov 2020

Reply Repost Favourite

「チペピジン」の咳止めとしての効果を調べようと思って論文を漁っていると、徐放剤がADHD治療薬として研究されていることを知って驚いている(´･ω･`) < drug repositioning BMC Psychiatry . 2020 Nov 10;20(1):530. https://t.co/WOlSkuecio

14 Nov 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.